Incorporates an active component that will significantly shorten the treatment duration of MPE compared to current catheter devices.
A user-friendly design to promote patient independence, comfort and quality of life.
Reduces the costs associated with long-term home drainage and acute readmissions to hospital.
Posted in News by Nate Reynolds
7th June, 2024
Natalie Walsh, from University of Galway IdeasLab, presented the Empathy Studio in partnership with Boston Scientific and SymPhysis Medical at the University Industry Innovation Network (UIIN) conference in Madrid last...
Read more
Posted in News by Nate Reynolds
6th June, 2024
SymPhysis Medical CEO, Tim Jones, and VP of Marketing & Sales, Joe Villanova, had the privilege of joining fellow respiratory and pulmonology innovators at the recent American Thoracic Society Respiratory...
Read morePosted in News by Nate Reynolds
19th December, 2023
What a year it has been! Finishing on what has been an eventful year, Symphysis Medical are extremely grateful for days like Thursday, 7th December, 2023 at the Irish Medtech...
Read more
Posted in News by Nate Reynolds
20th November, 2023
November is proving to be a fruitful month this year as SymPhysis Medical have been nominated for not one but three awards. Firstly, the Excellence in Innovation Award is a part...
Read more
Affects ~90% of patients with mesothelioma.
Affects ~ 35% of patients with lung cancer.
Affects ~ 16% of patients with breast cancer.
Affects ~ 11% of patients with lymphoma.
